Let’s start up with the current stock price of Iterum Therapeutics plc (ITRM), which is $1.00 to be very precise. The Stock rose vividly during the last session to $1.07 after opening rate of $1.05 while the lowest price it went was recorded $1.02 before closing at $1.03.
Recently in News on May 7, 2021, Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021. Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Friday, May 14, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business. You can read further details here
Iterum Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.9950 on 02/11/21, with the lowest value was $0.9300 for the same time period, recorded on 05/11/21.
Iterum Therapeutics plc (ITRM) full year performance was -70.40%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Iterum Therapeutics plc shares are logging -83.31% during the 52-week period from high price, and 122.84% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.45 and $6.02.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3499549 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Iterum Therapeutics plc (ITRM) recorded performance in the market was 4.15%, having the revenues showcasing -33.12% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 177.60M, as it employees total of 7 workers.
The Analysts eye on Iterum Therapeutics plc (ITRM)
During the last month, 0 analysts gave the Iterum Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.4158, with a change in the price was noted +0.0713. In a similar fashion, Iterum Therapeutics plc posted a movement of +7.59% for the period of last 100 days, recording 19,298,801 in trading volumes.
Technical rundown of Iterum Therapeutics plc (ITRM)
Raw Stochastic average of Iterum Therapeutics plc in the period of last 50 days is set at 8.65%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 23.91%. In the last 20 days, the company’s Stochastic %K was 29.45% and its Stochastic %D was recorded 28.31%.
Considering, the past performance of Iterum Therapeutics plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 4.15%. Additionally, trading for the stock in the period of the last six months notably improved by 106.00%, alongside a downfall of -70.40% for the period of the last 12 months. The shares increased approximately by -11.97% in the 7-day charts and went up by -21.97% in the period of the last 30 days. Common stock shares were lifted by -33.12% during last recorded quarter.